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Abstract
Background: The RNA interference (RNAi) pathway is a mechanism of gene-suppression with
potential gene therapy applications for treating viral disease such as HIV-1. The most suitable
inducer of RNAi for this application is short hairpin RNA (shRNA) although it is limited to
suppressing a single target. A successful anti-HIV-1 therapy will require combinations of multiple
highly active, highly conserved shRNAs to adequately counter the emergence of resistant strains.
Results: We calculated the percentage conservations of 8, 846 unique 19 nucleotide HIV-1 targets
amongst 37, 949 HIV-1 gene sequence fragments containing 24.8 million 19 mers. We developed a
novel method of determining conservation in 'profile' sets of 5 overlapping 19 mer sequences
(covering 23 nucleotides in total) to ensure that the intended conservation of each shRNA would
be unaffected by possible variations in shRNA processing. Ninety six of the top ranking targets from
22 regions were selected based on conservation profiles, predicted activities, targets and specific
nucleotide inclusion/exclusion criteria. We constructed 53 shRNAs with 20 bp stems and 43
shRNAs with 21 bp stems which we tested and ranked using fluorescent reporter and HIV-1
expression assays. Average suppressive activities ranged from 71 – 75%, with 65 hairpins classed as
highly active (> 75% activity). Overall we found little difference in activities from minor changes in
stem length (20 cf. 21), or between neighboring targets differing by a single nucleotide in start
position. However, there were several exceptions which suggest that all sequences, irrespective of
similarities in target site or design, may be useful candidates. We encountered technical limitations
with GFP reporter assays when the target domain was long and or when the distance between the
target site and fusion junction was large. Assay performance was improved by dividing large targets
into several shorter domains.
Conclusion: In summary, our novel selection process resulted in a large panel of highly active
shRNAs spanning the HIV-1 genome, representing excellent candidates for use in multiple shRNA
gene therapies. Our core selection method ensuring maximal conservation in the processed
product(s) is also widely applicable to other shRNA applications.
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Background
Human Immunodeficiency Virus type I (HIV-1) is a posi-
tive strand RNA retrovirus that causes Acquired Immuno-
deficiency Syndrome (AIDS) resulting in the destruction
of the immune system and ultimately leading to death
from opportunistic infections. UNAIDS/WHO estimate
that there are ~30 – 36 million people currently infected
with HIV, making it one of the worst pandemic infections
in history [1]. HIV is characterized by high genetic varia-
bility which, in combination with the scale and duration
of the pandemic, has resulted in the emergence of many
hundreds of genetically unique strains which are classified
into several major groups (M, N, and O) and then further
into subtypes or clades [2,3]. There is a geographical clus-
tering for each group and subtype, with group M the main
grouping distributed globally, and clade B the most com-
mon subtype found in the USA and Europe [3]. Such
sequence diversity facilitates viral escape from immune
surveillance as well as emergence of antiviral drug resist-
ance, thereby posing serious challenges for the design of
vaccines and antiviral therapies.
RNAi is a recently discovered phenomenon that has the
potential to be exploited in Gene therapy strategies for
HIV-1 (for review see [4-6]). In mammalian cells RNAi
begins with a double-stranded RNA inducer that is pro-
gressively processed from its termini by RNase III type
endonucleases, firstly Drosha in the nucleus followed by
Dicer in the cytoplasm, to yield a short interfering RNA
(siRNA) duplex [7,8]. The duplex is unwound and loaded
into the RNA induced silencing complex (RISC) in a proc-
ess that favors one of the 2 strands (the guide strand)
based on a difference in thermodynamic stability at the
ends of the duplex [9]. The most ubiquitous natural effec-
tors of mammalian RNAi are microRNA which are small
hairpin-like RNA transcripts implicated in regulation of
gene expression [10,11]. The most suitable artificial RNAi
inducers available for integration into current gene ther-
apy treatments are short hairpin RNAs (shRNAs). Sharing
structural similarities to natural microRNA, shRNA con-
sists of a short single stranded RNA transcript that folds
into a 'hairpin' configuration by virtue of self-comple-
mentary regions separated by a short 'loop' sequence. Sev-
eral groups simultaneously developed U6 and H1
polymerase III (pol III) promoter expression systems to
deliver shRNAs, exploiting their well-defined transcrip-
tion start and end points [12-19]. There are now several
different single shRNA forms in use. These can be gener-
ally divided into the traditional shRNAs with short (19 –
21 bp) or long (up to 29 – 30 bp) fully matched stems and
several different miRNA-like variants that may incorpo-
rate bulges, mismatches and more complex loops [20-25].
With highly active molecules obtainable from all the
above formats, we chose to use traditional short shRNAs
in this study as they best fitted our design strategy.
The potency of individual shRNA directed to HIV-1 or its
cellular receptors has now been extensively demonstrated
in culture (summarized in [26,27]). However, studies
examining prolonged silencing of replicating HIV-1 over
time have found that the emergence of viral escape
mutants occurs rapidly and can render a highly active
shRNA ineffective in less than 1 month [28,29]. HIV-1
resistance to shRNA has been shown to occur through
small sequence changes which alter the structure or
sequence of the targeted region [29,30]. Thus, rather than
circumventing the RNAi response per se, HIV-1 escape
mutants have thus far only rendered individual shRNA
ineffective. Mathematical modeling and related studies
suggest that combinations of perhaps as few as 4 different
hairpins may effectively curb the emergence of viral
escape mutants [27,31,32]. Hence, there is a need for a
collection of highly active, highly conserved shRNAs
against HIV-1 for assembly into combinations.
There are over 170 published siRNAs and shRNAs report-
edly tested against HIV-1. Two studies, by ter Brake et. al.
(2006) and Naito et. al. (2007), have each contributed
large sets of sequences specifically designed to be con-
served in different viral strains [33,34] (Additional file 1).
ter Brake et. al. scanned 170 complete HIV-1 genomes,
irrespective of clade, in 20 nucleotide (nt.) windows and
identified 19 highly conserved regions that matched at
least 75% of these [34]. The authors created 86 partially
overlapping shRNAs without considering predicted activ-
ities, and measured suppressive activities with a replicat-
ing HIV assay. While their shRNAs were designed with 19
bp stems, a loop sequence was used with potential to par-
tially collapse through self complementarity, thus likely
resulting in 21 bp stems [12,35-37]. Only 1 in 4 shRNAs
was highly active, a figure in line with expectations of
activity from randomly selected siRNAs [38-42]. In the
second study, Naito et. al. scanned 495 near-complete
HIV-1 group M genomes in 21 nt. windows and identified
216 sequences that were conserved in > 70% of strains
[33,43]. Twenty three highly-conserved and 18 moder-
ately-conserved sequences were selected with a bias
towards those with high predicted activities. These
sequences were synthesized as siRNAs with 21 bp
duplexes plus 2 nucleotide overhangs and tested for sup-
pressive activity by measuring degradation of a reporter
mRNA via RT-PCR. Thirty nine of the 41 siRNAs tested
were found to be > 60% active. However, these findings
may not directly translate to shRNA studies as siRNA activ-
ity is not necessarily maintained in corresponding shR-
NAs.
Although most traditional shRNA design begins with a
designed 19 nucleotide siRNA core, the success of siRNA
to shRNA conversion is not guaranteed. There is still
uncertainty surrounding shRNA processing and the pre-Retrovirology 2009, 6:55 http://www.retrovirology.com/content/6/1/55
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cise identity of the processed siRNA products. Rigid con-
servation estimates used to design the shRNA stem may be
invalidated if the sequence of the processed siRNA prod-
uct(s) differs from that intended. This could occur if flank-
ing and or loop sequences were incorporated during
processing into the processed siRNA(s). Sequences exter-
nal to the shRNA stem are not commonly designed to
match the target, and hence not often considered in esti-
mates of target conservation.
The aim of this study was to create a collection of highly
active and highly conserved shRNA target sequences for
HIV-1 using all available sequence information, such that
intended conservation levels would be maintained in the
processed siRNA product(s). We made 96 shRNAs using a
novel method for selecting shRNA targets with conserva-
tion 'profiles' that consider 5 overlapping 19 nt. sequences
per target, and tested their activities with fluorescent
reporter and HIV expression assays.
Results
Nomenclature of an shRNA core design for variable shRNA 
processing
We developed a novel shRNA design method to ensure
that the processed siRNA product(s) retained their
intended level of conservation irrespective of possible var-
iations in shRNA processing (Figure 1). Each hairpin in
this study was designed around a 19 bp siRNA target that
we positioned at the base terminus or 'open' end of the
shRNA shown to be the primary region responsible for
suppressive activity [44]. We called the 19 mer siRNA tar-
get the 'primary core', and the first nucleotide of this core
the 'p0' position. The 2 adjacent overlapping 19 mers 1
and 2 nucleotides upstream of the p0 position were
referred to as the p-2 and p-1 positions, and the equiva-
lent downstream ones were p+1 and p+2. By also consid-
ering the conservation of the surrounding sequences, our
design ensures that even if shRNA processing shifts within
1 – 2 nucleotides from the expected p0 position, the
resultant siRNA guide strand(s) will remain fully matched
to the target.
Assembling the HIV-1 data for conservation analysis
HIV-1 sequence data was compiled from 2 sources; pub-
licly available sequence from the Los Alamos National
Laboratory (LANL; http://www.hiv.lanl.gov) and proprie-
tary sequence information from Virco http://www.virco
lab.com (Additional file 2). The LANL data set included
all near full-length genome sequences and gene sequence
fragments as of December 2006. HIV-2 and SIV sequences
were examined and excluded as they were sufficiently
divergent to the NL4-3 HIV-1 reference strain [Gen-
bank:AF324493]. The Virco data set was a small, but
highly relevant private data set obtained from 105 HIV-1
infected persons from Europe. It contained only gene-spe-
cific sequences for the 6 accessory genes; Tat, Rev, Vif, Vpu,
Vpr and Nef. The combined HIV-1 data set contained 24,
861, 276 separate 19 mers from 37, 949 individual partial
gene sequences. These sequences spanned the 6 accessory
genes, the 3 core poly-protein genes and the long terminal
repeat (LTR).
Creating the shRNA target set
We made a bioinformatic tool to compile potential 19
mer HIV-1 targets by sub-dividing the sequence of the
NL4-3 strain into gene-specific sets (Additional file 2).
The NL4-3 laboratory strain was chosen for a reference
strain to match our reporter sequences and to evaluate the
activity of all potential targets. By using individual gene
sets we generated 8, 846 unique 19 mer sequences,
excluding overlapping targets and LTR duplicate
sequences. Due to several inter gene gaps, we omitted
~2% of potential targets, including the highly structured
psi (ψ) region between the 5' LTR and Gag.
Core placement and the surrounding nucleotides Figure 1
Core placement and the surrounding nucleotides. 
The shRNAs in this study were built around a designed 19 
nucleotide siRNA core. We positioned the core at the base 
terminus of the shRNA (the open end), and extended the 
stem as necessary at the loop terminus (to 20 or 21 bp). The 
lower strand, or anti-sense strand region, was designed to be 
the intended siRNA guide strand which was therefore com-
plementary to the target. Our shRNAs were designed so 
that the position of the first nucleotide of the primary core 
(p0) corresponds with the first base pair at the base termi-
nus. The positions of the first and last nucleotides of the 
flanking p-2, p-1, p+1 and p+2 positions in the expected guide 
strand are shown (- positions in blue, + positions in purple). 
We considered the sequence of these flanking bases when 
selecting targets and estimating core conservations as it is 
presently unclear if these positions are incorporated in the 
processed siRNA product(s). The example shown is for a 20 
bp stem, so that the last nucleotide of the p+2 position is 
also the last nucleotide of the loop. Likewise, shRNAs with 
21 bp stems, the last nucleotide of the p+2 position is the last 
nucleotide of the stem.
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Calculating conservations
We made another tool to determine the percentage con-
servation of any given 19 mer within the HIV-1 sequence
sets. Conservations were calculated by sequentially com-
paring each 19 mer from the NL4-3 gene sets against each
19 mer in the corresponding 24.8 million HIV-1 variant
gene sets in more than 44.5 billion comparisons. Only
perfectly matched sequences were considered. We created
a 'conservation profile' of 5 overlapping sequences for
each NL4-3 19 mer core that included conservation esti-
mates for the p0 primary core sequence, and the 2 flank-
ing sequences on either side: p-2, p-1, p+1 and p+2. Each
conservation profile was calculated in several groups: all
subtypes, LANL clade B only, and accessory gene Virco
sequences. The percentage conservation for the total 23
mer in each profile set was also calculated and considered.
In addition to conservations, we also generated predicted
activities using the Reynolds et. al. siRNA design rules
[39], and recorded the gene or protein products for each
core.
We found that 2.8% of the 19 mers were > 70% conserved
across all subtypes and 0.5% were > 90% conserved. Con-
servations were higher for the clade B subtypes, with 14%
> 70% conserved and 1.2% > 90% conserved, being
derived from the LTR, Pol, Vif and Env regions. We also
found 0.5% of LTR sequences were 100% conserved in all
clade B subtypes. There was at least one 19 mer from each
gene that was conserved in at least 80% of LANL clade B
sequences, with the exceptions of Vpu, Rev and Vpr which
was the most poorly conserved. The most highly con-
served Vpr sequence was conserved in 57% of LANL clade
B sequences, and in only 36% of sequences from all
clades. We found there was a > 10% difference in conser-
vation of the p0 and p +- 1 positions for 7% of potential
targets, and a > 10% difference in conservation of the p0
and p +- 2 positions for 14% of potential targets.
Core selection criteria
Target selection was based on a combination of conserva-
tions, predicted activities, target diversity and specific
nucleotide inclusion and exclusion criteria in line with
our described shRNA design method. The centrally
located p0 19 mer was considered the most important. We
typically disregarded p0 19 mers if the conservations of
flanking positions were notably reduced (p +- 1 > 5% or p
+- 2 > 10%), or if the total conservation of the entire 23
mer region was low. We filtered all potential 19 mers to
remove those with consecutive runs of 4 or more 'T' or 'A'
nucleotides to avoid the formation of pol III termination
signals within the shRNA stem. We placed a bias to select
sites where the initiating nucleotide at p0 was a purine ('A'
or 'G') for efficient initiation of pol III transcription [45].
Where possible, we selected the primary cores so that the
sequence of the first and the second nucleotides upstream
of the p0 core starting position were purines to match
potential 'U' remnants incorporated at the 3' end of the
guide strand(s) via pol III termination.
The chosen cores
96 targets were selected and came from 22 distinct regions
containing highly conserved sequence (Figure 2) (Addi-
tional file 2). Fourteen of these regions were unique when
compared with previously published anti-HIV siRNAs and
shRNAs. There was at least one core targeted to all gene
fragment sets, excluding Vpr. The 96 targets consisted of 8
to the LTR, 9 to Gag, 32 to Pol, 7 to Pol/Vif (overlapping
gene targets), 7 to Tat/Rev, 12 to Vpu, 16 to Env, 2 to Env/
Rev, 3 to Nef/LTR (Figure 3). The average conservation
profile of the 96 cores was 65 – 67% for all clades, and 78
– 80% for the LANL clade B sequences. While the average
conservations of all 5 positions in our top ranking target
profiles were intentionally close, there were several pro-
files with as much as a 70% difference in conservation
between p0 and one of the flanking positions. The conser-
vation estimates using the Virco data set were within 2%
of the corresponding LANL data set across all clades. For
comparison, we calculated the conservations for 100+
previously published targets and found that less than a 1/
4 were greater than 70% conserved, being on average only
~34 – 45% conserved across all clades (Additional file 1).
The LTR regions were the most highly conserved with two
23 mer target profiles (#7 and #8) matched in over 90%
of all clades. There were also 3 LTR targets (#2 – #4) con-
served in at least 97% of LANL clade B sequences, and 4
(#5 – #8) that were 100%. Other targets that were highly
conserved in LANL Clade B included 6 Vif targets (#51 –
#56) and 1 Pol target (#42) matching at least 89% and
91% respectively. The chosen cores were made into 53
hairpins with 20 bp stems, and 43 hairpins with 21 bp
stems. The 19 nt. cores were made into 20 and 21 bp
stems by extending each primary core 1 or 2 nt. at the 3'
or loop end to match the p+1 and p+2 target positions. We
made 14 matched pairs: targets that had both a 20 bp and
21 bp hairpin. Where possible, the remaining sequences
external to the core were selected to match the target (as
detailed in Additional file 2). Synthetic oligonucleotide
templates were prepared for each shRNA, and assembled
in standard plasmids for expression by the human H1
promoter.
Screening for inherent suppressive activity
The suppressive activity of each hairpin was initially
screened using gene-specific fluorescent fusion reporters
in a transient expression assay. Each reporter contained
GFP fused upstream to one of the accessory genes, core
genes or the LTR with stop codons placed between the 2
domains. Thus, each reporter produced a fused mRNA tar-
get comprised of GFP plus the HIV-1 gene from whichRetrovirology 2009, 6:55 http://www.retrovirology.com/content/6/1/55
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Conservations and the 22 targeted regions Figure 2
Conservations and the 22 targeted regions. The position and length of each gene in NL4-3 is shown above the corre-
sponding position in the conservation graph for NL4-3. Conservations were calculated for 8, 846 19 mers from the NL4-3 
gene sets against 24.8 million 19 mers in the corresponding HIV-1 variant gene sets, and plotted as conservations for all sub-
types, and the clade B only subtypes. The NL4-3 genomic co-ordinates for the starting position of the 22 regions covering the 
96 selected targets are given below the conservation graphs. The 22 regions and their component targets (divided into the tar-
gets made as hairpins with 20 and 21 bp stems) are shown at the bottom. Region numbers in red are the regions that have 
overlapping gene targets (e.g. region 1 hairpins include #1, #95 and #96, and target both the LTR and Nef). Regions 1, 2 and 3 
within the LTR are repeated in light grey to indicate their overlapping target positions.
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Sequence and conservation profiles for the 96 targets Figure 3
Sequence and conservation profiles for the 96 targets. The sequences of the 96 targets are shown in their 22 overlap-
ping regions. The label column (left) shows the region number, the target gene, the target co-ordinates (relative to the start of 
the gene) and the number of shRNAs in each group. The sequence column (right) shows the shRNA # above the first nucle-
otide of the p0 position. shRNA #s shown in red are target start positions shared by two matched shRNAs; 20 and 21 bp stem 
shRNAs. The percentage conservations of 19 mer windows in all clades, and clade B subtypes only, are shown as colored-
coded circles below the starting position of each 19 mer sequence within the profile sets of 5 overlapping sequences. Total 
conservations for each region are similarly shown at the end of each region. shRNA #s generally proceed in order, except for 
#95 and #96, which were selected from the Nef target set but are shown on their overlapping LTR target (region 1). An exam-
ple was made of shRNA #1 with its p0 and p+-1 and p +-2 position 19 mer sequences indicated in more detail.
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only the GFP domain was translated. This was engineered
to remove the possibility of HIV-1 protein products affect-
ing hairpin activity. Each hairpin expression plasmid was
co-transfected with 2 reporters; the corresponding target-
specific GFP fusion and a non-specific AsRed-1 fusion
(Clontech fluorescent proteins). Target-specific and non-
specific effects on fluorescence levels were measured rela-
tive to the fluorescence levels from the plasmid backbone
sample after 48 hours of hairpin and reporter expression.
We have previously optimized the assay conditions to
enable an approximate comparison of both target-specific
suppressive activities and non-specific activities across
reporters. Normalized suppressive activities were calcu-
lated by removing the overriding non-specific activity
component from the apparent suppressive activity meas-
urements.
The average suppressive activity across the 96 hairpins was
63%; i.e. the presence of the shRNA reduced the average
level of fluorescence to 37% of the unsuppressed control
(Figure 4a). Twenty two hairpins were highly active (>
75% suppressive activity), 56 were active (between 50 and
75% activity) and 18 were inactive (< 50% activity). Non-
specific activities varied widely and mostly enhanced the
fluorescence levels, but did not appear to correlate to sup-
pressive activity. While the mechanism and significance of
non-specific signal enhancement is not known, it is a phe-
nomenon that we have commonly observed and have pre-
viously determined to be sequence-specific, dose-
dependent and highly reproducible [44].
Reporter length and the distance between the target site 
and the fusion junction can affect apparent suppressive 
activity
While we observed an expected spread of suppressive
activities, the average level for the shRNAs measured with
the core-gene reporters was generally lower than that
observed for the shRNAs measured with the accessory-
gene reporters. We observed an average percentage fluo-
rescence of 38% for Gag, 42% Pol, 52% Env reporters vs.
46% Nef-LTR, 19% Tat exons 1 and 2, 10% Vpu and 13%
Rev exon 2 reporters. We also noted that the target
domains for the core-gene reporters were longer than the
accessory gene reporters. The lengths of the target
domains ranged from 1, 503 – 3, 012 bp for the core gene
reporters but only 243 – 921 bp for the accessory genes.
The shRNA target sites in the long-core reporters were also
generally further away from the fusion junction between
the GFP and gene-target domains. A second set of shorter
core-gene reporters were constructed to determine if the
length of the target domain and or the distance of the tar-
get site from the fusion junction was affecting apparent
suppressive activities (Figure 5). The length of these short-
ened reporters ranged from 425 – 650 bp and all match-
ing hairpins were re-assayed.
There was a noticeable shift in the activities of most hair-
pins when assayed with both long and short reporters
(Figure 4b). The majority of hairpins were more active
when assayed with the short reporters, with the average
percentage fluorescence ranging from 18 – 51% (com-
bined average of 29%) compared to 39 – 58% (44% com-
bined) with the longer reporters. The percentage
fluorescence across the 96 hairpins including the shorter
reporters was improved from an average of 37% to 25%.
Sixty five hairpins were now regarded as highly active (cf.
22), 19 were active (cf. 55) and only 12 were inactive (cf.
19). As the activity data was not normally distributed, we
performed a Wilcoxon signed rank test, the non-paramet-
ric equivalent of a paired t-test, to statistically compare the
activities of the shRNAs from the matched long and short
reporters (Figure 6a). This confirmed that the change in
activity was due to a change in reporter length (P <
0.0001). We also plotted the suppressive activity against
the distance of the target site from the fusion junction for
all hairpins tested (Figure 6b). A non-parametric analysis
of this data showed that there was a significant correlation
between the apparent activity and distance of the target
site from the fusion junction (Spearman correlation co-
efficient of 0.53). However, even though there was a sig-
nificant correlation, the large scatter suggests that there
may be other compounding factors such as alternate sec-
ondary structure formations and changes in target-site
accessibility.
Comparing matched pairs with 20 and 21 bp stems
The 96 hairpins were comprised of 53 hairpins with 20 bp
stems, and 43 hairpins with 21 bp stems. The average per-
centage fluorescence for the hairpins with 20 bp stems
was 31%, with 30 scored as highly active. The average per-
centage fluorescence for the 43 hairpins with 21 bp stems
was 18%, with 35 scored as highly active. As the hairpins
in each group were selected individually, and hence were
mostly unmatched, it was not possible to determine from
this analysis if either length was necessarily more active.
There were, however, 14 matched pairs of hairpins with
20 and 21 bp stems designed to the same target site. A sta-
tistical analysis of these with a Wilcoxon signed rank test
showed that there was no overall significant differences in
activity (p = 0.8077), although a few pairs, #45 | #46, #80
| #81, #85 | #86, exhibited notable changes (Figure 6c).
Comparing hairpins with adjacent, overlapping targets
Seventy three adjacent pairs of hairpins had starting posi-
tions that differed by 1 nucleotide. There was a > 10%
change in activity for more than a quarter of the pairs
which had an average change in activity of 32%. Forty-two
of the 73 pairs had the same stem length which enabled
us to compare their activities with a Wilcoxon signed rank
test showing that there was no significant difference (p =
0.1077) (Figure 6d). Pairing was effective in accountingRetrovirology 2009, 6:55 http://www.retrovirology.com/content/6/1/55
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Suppressive activities measured with fluorescent reporters Figure 4
Suppressive activities measured with fluorescent reporters. Suppressive activities were screened using gene-specific 
fluorescent fusion reporters in a transient expression assay. The 96 hairpins were individually transfected with a target-specific 
GFP fusion reporter, and an AsRed-1 non-specific reporter. Specific activity is shown as percentage fluorescence of the unsup-
pressed control (black bars above; control shown in blue), and non-specific activity is shown as the fold difference (normaliza-
tion factor) relative to the baseline non-specific activity of the unsuppressed control (red bars below, control shown in blue). 
E.g. a normalization factor of 1 is no non-specific activity, a value of 2 is twice as much non-specific activity of the baseline con-
trol (set at 1). Categorical markers divide the hairpins into inactive, active and highly active groups. The reporter used for each 
hairpin (green bars), and the 22 targeted regions (brown bars) are also shown. (a) Suppressive activities measured with the 
first round 'long' (core genes) and 'short' (accessory genes) reporters. (b) The previous long reporters were replaced with a 
series of shorter fragment reporters and suppressive activities were remeasured. The suppressive activities form the previous 
short accessory gene reporters are included for comparison (hollow bars).
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for variability indicating that in most cases, activity for the
2 neighboring sites were similar (r = 0.59, p < 0.0001, one-
tailed test). However, there were some notable exceptions
such as the pairs #26 | #28 and #44 | #47 for which the 1
base difference had a major impact on activity.
Screening for anti-HIV-1 activity
All shRNAs were also tested in the NL4-3 HIV-1 expres-
sion assay. In this assay, shRNA expression plasmids were
co-transfected with the pNL4-3 HIV-1 expression plasmid
and total p24 levels were measured 2 days later. Activity
was calculated as a relative percentage of the baseline p24
levels present in the plasmid backbone sample. In this
assay, the average percentage p24 for the 96 hairpins was
29% of the unsuppressed control. Sixty five were classed
as highly active, 16 were active and 15 were inactive (Fig-
ure 7). These groupings closely matched those from the
gene fusion assay using the shorter reporters, with several
exceptions. These exceptions could be due to differences
in target structure and accessibility to the target site, or to
influences from non-specific activities which were not dis-
tinguishable in the current format of this assay. It should
also be noted that the suppressive activities for the highly
active hairpins in the NL4-3 assay generally appeared
greater than those observed in the gene fusion assay. How-
ever, we consider that this was likely due to differences in
assay dynamics such as different shRNA to target ratios,
target production times, etc. Importantly, the overall cate-
gorical and relative ranking of hairpins based on suppres-
sive activities were similar in both assays.
Short-listing the best sequences
We created a scoring method to rank the 96 hairpins for
overall performance based on their suppressive activities,
non-specific activities and percentage conservations. Each
parameter was weighted approximately equally and
awarded a score out of 100. Suppressive activities from
both assays were tallied as 100 minus the percentage flu-
orescence value or percentage p24 graphed; e.g. a graphed
value of 14% fluorescence scored an 86. Non-specific
activity was awarded a top score of 100 for no activity if
the shRNA had a normalization factor of 1.0. This was
reduced accordingly for increased non-specific activity,
e.g. a normalization factor of 1.2 (0.2 fold enhancement)
or 0.8 (0.2 fold reduction) was only awarded 80, and so
on. The percentage conservations were also tallied using
the p0 position. According to this method, the 10 overall
best performing hairpins from this study were: LTR 510-
21 (#5), LTR 527-21 (#8), LTR 509-20 (#4), Env 1428-21
(#84), Tat 131-20 (#58), Tat 132-21 (#59), Env 1425-21
(#82), Env 1426-21 (#83), LTR 516-21 (#6), and Gag
532-21 (#11) (Additional file 2). For all 10 hairpins the
percentage conservations for the p +- 1 and 2 positions
were within 8% of that for the p0 position. This method
of ranking was only one of many available, and a bias
towards activity, or conservations may be more suitable
for other applications.
Discussion
The aim of this study was to create a collection of hairpins
against HIV-1 that are suitable for potential inclusion in
multiple hairpin gene therapies. We developed an original
method to analyze conservations for each potential 19
nucleotide target and derive 'conservation profiles' to
maximize the likelihood of maintaining conservation of
the processed siRNA product(s) in the absence of detailed
mechanistic information regarding shRNA processing. We
selected 96 of some of the theoretical best targets, assem-
bled them into shRNAs consistent with our design
method, and characterized their activities using fluores-
cent reporter and replicating HIV-1 assays. The hairpins
were ranked and shortlisted to highlight those potentially
most suitable for inclusion in multiple shRNA gene ther-
apies.
The relevant previous studies have used only 170 – 495
full-length HIV-1 genome sequences to estimate conserva-
tion, or the equivalent of 1530 – 4455 sequences if subdi-
vided into individual gene sequences; just 4–11% of the
sequences considered here [33,34]. In this study we exam-
ined close to 38 thousand partial sequences which
included sequence information from the full-length
genome data set fragmented into separate genes. There
are, however, some limitations with the partial sequence
set, and the LANL data in general. Some of the partial gene
sequences are likely duplicate entries of sequence from the
same patient, which may skew conservation estimates.
However, we have compared all sequences within each
gene set and found that on average 82% of sequences were
unique. Therefore, our analysis contained ~7 – 20 times
the number of sequences used in previous studies. We
compared our conservation estimates for a set of 100+
previously published sequences against those estimated
by others, and found that while many conservations were
similar, some differed widely (Additional file 1) [33].
Secondly, the sequences in the LANL and Virco databases
were biased towards clade B sequences from studies in the
US and Europe with an average of 45% of the sequences
in each being clade B. Unfortunately the greatest diversity
of Group M sequences is likely to be found in places like
the Democratic republic of Congo which do not have the
resources for large-scale sequencing. However, at this
stage of gene therapy development, clade B sequences are
still the most relevant as trial sites, access to infrastructure
and the initial cost of treatment will likely restrict early
gene therapy to the US, Europe and other developed
regions. The Virco data set was generated to represent a
broad cross section of HIV-1 patients likely to be included
in future European gene therapy trials. For this reason,Retrovirology 2009, 6:55 http://www.retrovirology.com/content/6/1/55
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approximately half of these patients were selected because
they had been infected with Clade B.
The suppressive activities of our hairpins were first tested
with a fluorescent reporter assay, followed by a more bio-
logically relevant HIV-1 expression assay. The fluorescent
reporter assay has higher throughput and can estimate
inherent suppressive activity whilst providing an indica-
tion of non-specific activity. Fluorescent reporter systems
are now widely used for estimating suppressive activity.
However, here we show that their use is not always
straightforward. For reporters with the target domain
shRNA target sites mapped to the 13 fluorescent reporters Figure 5
shRNA target sites mapped to the 13 fluorescent reporters. The target sites of the 96 shRNAs were mapped to the 
13 fluorescent reporters. The 4 short accessory genes and LTR reporters are shown down the left, and the 3 long core gene 
reporters are shown down the right. Mapped onto the long core gene reporters were the corresponding 6 short gene frag-
ment reporters made to retest the core gene shRNAs. Lengths are to scale to show the relative distances between the target 
sites, fusion junctions and total reporter lengths. n.b. some shRNAs were assayed with a different reporter to that of the gene 
targeted due to overlapping target sequences, e.g. the Vif matched shRNAs #51 – 57 were assayed with Pol reporters.
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fused downstream of the fluorescent domain, we found
that the length of the reporter and or the distance of the
target site from the fusion junction can affect the apparent
suppressive activity. This may be due to a delay between
the cleavage event and complete target degradation per-
mitting some translation. Alternate secondary structure
formations and changes in target-site accessibility are also
likely to be contributing factors as shown in many previ-
ous reports [30,46-51]. We do not expect that all hairpins,
if measured using both a long and short reporter, will
show a change in activity for a change in distance. If a hair-
pin was entirely inactive in a short reporter we would not
expect its activity level to improve with a change in
reporter length. Similarly an extremely active hairpin may
cleave its target with such high efficiency that even mod-
erate changes in reporter length or distance from the
Reporter length, target distance, matched and overlapping hairpin pairs Figure 6
Reporter length, target distance, matched and overlapping hairpin pairs. (a) The suppressive activities of hairpins 
that were assayed with both long core gene reporters and shorter core gene fragment reporters, were plotted and grouped 
according to reporter length. (b) Suppressive activity was plotted against the distance of the target site from the fusion junction 
for all hairpins tested. (c) The suppressive activities of 14 matched pairs of hairpins with 20 and 21 bp stems designed to the 
same target sites. (d) The suppressive activities of 73 pairs of neighboring hairpins with target sites a single nucleotide apart.
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Impact on HIV-1 expression Figure 7
Impact on HIV-1 expression. Anti-HIV-1 suppressive activity was tested by transfecting each shRNA expression plasmid 
with the NL4-3 expression plasmid. Activities were measured as a reduction in, and expressed as percentage of, p24 produc-
tion (measured as pg/ml) relative to p24 production from the unsuppressed control (shown in blue). The 96 shRNAs were 
measured in 3 sets (as indicated in purple) with 2 or more replicate experiments in each set (accessory gene shRNAs in one 
set, Gag plus Env shRNAs together, and Pol shRNAs separately).








  

$VVD\JURXS
$VVD\JURXS
$VVD\JURXS


S




R
I

F
R
Q
W
U
R
O

        
                  

+DLUSLQ
&RQWURO
,QDFWLYH
+LJKO\DFWLYH
$FWLYHRetrovirology 2009, 6:55 http://www.retrovirology.com/content/6/1/55
Page 12 of 15
(page number not for citation purposes)
fusion junction may be inapparent. We believe hairpins
with intermediate suppressive activities of ~10 – 90% will
be most sensitive to changes in reporter length. This issue
warrants further and specific investigation, especially
given the widespread use of fluorescent reporter assays.
When we examined 20 and 21 bp stems that shared the
same core start site, but differed by 1 nt. at their 3' ends,
we found that overall a single nucleotide change in stem
length had no statistically significant effect on suppressive
activity. We were interested in comparing these activities
since we had previously found that hairpins with 20 bp
stems may be processed into fewer products than the
more common 21 bp hairpins [44]. Our current study
demonstrates that hairpins with 20 bp and 21 bp stems
sharing a common core start site are frequently equally
effective suppressors. With no change in the core start site,
the primary siRNA product(s) may be unchanged. How-
ever, this may only be a general rule as in some instances
we did note differences in the activities of the 2 stem
lengths, affirming our need to better understand the
details of shRNA processing.
We also compared the activities of 2 overlapping hairpins
with target sites shifted by a single nucleotide, and for
hairpin pairs with the same stem length found no overall
significant difference in activities. However, there were a
number of pairs with markedly different suppressive activ-
ities which is an observation that has also been noted by
others. One study reported 2 independent series of 3 over-
lapping 19 bp shRNA targets differing by a single nt each,
where the 1st and 3rd shRNAs were active, but the inter-
vening one was not [34]. This is in line with our current
understanding of shRNA processing, where short hairpins
are believed to be processed from the 5' open end or base
terminus, and of siRNA activity which is defined by spe-
cific nucleotide positioning relative to the ends [39,52-
54]. Even the smallest change in core start site may be
changing the siRNA(s) produced. For routine application,
designing shRNA for 2 neighboring sites is probably
unnecessary, although with the noted exceptions it may
be worth testing the alternative n +- 1 sites if the n site has
low activity, or if the region has a particularly useful
attribute such as high conservation.
The standard approach to finding suitable shRNAs for
HIV-1 suppression includes screening for suppressive
activity and or basing conservation estimates solely on the
designed core. But with the current gaps in our knowledge
of shRNA processing, such screens may select for shRNAs
that although active, may not be yielding the intended
siRNA(s). This is because ordinary shRNA designs gener-
ally do not consider the potential contribution of sur-
rounding sequence. Hence, the conservation for the actual
processed siRNA(s) may differ from the expected proc-
essed siRNA and not maintain activity on all viral sub-
types as predicted. Although we found that a large number
of our 8846 potential 19 mer target profiles were equally
conserved across all 5 positions, there were a significant
number that differed by 10% or more between the pri-
mary and p +- 1 (7%) and p +- 2 (14%) positions. Our
method reduced the variation in conservation within each
of our top ranking profiles to an average of 3%. Thus, all
of the selected sequences will remain highly conserved,
irrespective of processing discrepancies and the precise
sequence of the processed siRNA product(s). Moreover,
there is no foreseeable disadvantage in applying our
method now, even if it should turn out that shRNA
processing generates a single siRNA product identical to of
the intended core.
The results of this study will be of widespread use to oth-
ers, especially since there is unrestricted use of all the iden-
tified hairpin sequences. In the absence of a detailed
understanding of shRNA processing mechanisms our tar-
get selection and shRNA design methods ensure that the
resulting product(s) remain conserved as intended. More-
over, the method is likely adaptable to other viral diseases
with highly variable sequence. Our results regarding the
use of long fluorescent reporters, as well as the changes in
suppressive activity associated with target proximity and
minor changes in stem length add to our basic under-
standing and applied use of shRNA. The collections of
hairpins, both the entire theoretical set and those we
selected as most suitable, are valuable resources for others
working towards an RNAi therapy for HIV-1.
Methods
Sequence analysis tools
The tools for subdividing NL4-3 and the HIV-1 variants
into 19 mers, calculating conservations, filtering
sequences, and all other sequence manipulations were
written in Visual Basic using Excel as an interface (Micro-
soft Excel X for Mac, 2001).
Constructing 96 shRNA expression plasmids
The inserts for all but 3 of the shRNA expression plasmids
were built from a single synthetic oligonucleotide ~72 –
75 nt. long (Additional file 2). Each oligonucleotide tem-
plate consisted of a partial restriction enzyme recognition
site (Bam HI), the hairpin sense (or upper) sequence, a
loop sequence, the hairpin anti-sense sequence, a pol III
terminator sequence, and a second partial restriction
enzyme recognition site (Hind  III). A short primer
sequence (12 nt.) common to the 3' end of all oligonucle-
otides was also designed, annealed to each oligonucle-
otide template and extended with Phi-29 DNA
polymerase in a single-step isothermal extension reaction
to make double-stranded synthetic inserts that were then
digested to create 'sticky ends' and cloned as per standardRetrovirology 2009, 6:55 http://www.retrovirology.com/content/6/1/55
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procedures (as previously described) [35]. The remaining
3 shRNA templates were created from standard comple-
mentary oligonucleotide pairs with offset ends as each
shRNA core sequence contained an internal Hind III site
making it incompatible with the Phi-29 extension
method. Each insert was placed into a human H1 (pol III)
expression plasmid derived from pSilencer (Ambion). All
shRNA plasmids were propagated in GT116 E. coli cells; a
cell line specifically developed for the replication of hair-
pin containing plasmids and vectors (Invivogen). DNA
was extracted (Hi-speed Maxi-prep Kit, Qiagen), quanti-
tated in triplicate (Nanodrop) and was sequence con-
firmed, using a modified protocol where necessary that
enabled automated sequencing of shRNA expression plas-
mids possessing reaction-inhibiting secondary structure
[35].
Reporter plasmid construction
The fluorescent protein-target fusion reporter plasmids
were constructed using EGFP (from pd4-d4EGFP-N1, BD
Biosciences), AsRed1 (from pAsRed1-C1, BD Biosciences)
and HIV-1 sequences PCR amplified from variant NL4-3
[Genbank:AF324493] (Additional file 2). Each reporter
contained the fluorescent domain fused upstream of one
of the accessory genes, core genes or the LTR with stop
codons placed between the 2 domains to ensure that only
the fluorescent protein domain was translated.
Fluorescent reporter assay
Each shRNA expression plasmid was co-transfected with
two reporters; the corresponding target-specific GFP
fusion and a non-specific AsRed-1 fusion. The non-spe-
cific reporter was typically an AsRed-1-Vpr fusion, since
we selected no Vpr shRNA targets. HEK293a cells (sourced
from the American Type Culture Collection) were seeded
at a density of 5 × 105 cells per well (6 well plates; 2 ml of
medium). Cells were transfected 1 day later using 1 μg of
total DNA (400 ng of shRNA expression plasmid, 300 ng
of target plasmid and 300 ng of control plasmid) with 4
μl of Lipofectamine 2000 (Invitrogen) in OptiMEM (Inv-
itrogen) to a total volume of 100 μl/well. Cells were ana-
lyzed by flow cytometry ~48 hours later (FACsCalibur and
CellQuest Pro for Mac OS X, BD Biosciences). Target-spe-
cific suppression was measured as a decrease in green flu-
orescence (FL1 channel) and non-specific effects were
measured as a change in red fluorescence (FL2 channel).
The Fluorescence Index (FI) of cells in each channel was
calculated by multiplying the geo mean of fluorescence by
the percentage of cells that were fluorescent (only those
cells gated above background). The FI of FL1 (green, tar-
get-specific activity) was normalized to remove non-spe-
cific effects (FI of FL1 normalized to the FI of FL2) and was
expressed as a percentage of the FI of cells transfected only
with the control plasmid that expressed no shRNA. The
normalization factor was shown as a relative measure of
non-specific shRNA activity (a value of 1 equals no non-
specific activity, i.e. the measured non-specific activity was
identical to that measured for the control plasmid that
expressed no shRNA). Each sample was analyzed in tripli-
cate, and each experiment was repeated at least 3 times
with 95% confidence intervals shown (calculated from a
minimum of 9 points). Every experiment included a mock
transfection (i.e. no DNA) and an off-target shRNA con-
trol (to verify that on-target shRNA suppression was
sequence-specific) (Additional file 2); both of which
behaved as expected, and both of which were omitted
from the graphs for clarity.
HIV-1 expression assay
HEK293a cells were seeded at a density of 2 × 105 cells/
well (12 well plates; 1 ml of DMEM-10). Cells were trans-
fected ~24 hours later using 110 – 130 ng of shRNA
expression plasmid (equal molar amounts) and 800 ng
(3× molar amount of expression plasmid) of pNL4-3
reporter plasmid with Lipofectamine 2000 at a ratio of 1:
4 (μg DNA: μl Lipofectamine 2000) in OptiMEM to a total
volume of 200 μl/well. Medium was replaced with an
equal volume ~24 hours post-transfection and the cells
were harvested a further ~24 hours later by centrifugation
at 400 g for 10 min. at room temperature. Samples were
stored at -20 °C until assayed for p24 levels (a capsid pro-
tein required for HIV-1 virion production) via Enzyme-
Linked Immunosorbent Assay (ELISA) using the
INNOTEST HIV antigen mAb kit (Innogenetics). The sup-
pressive activity of each shRNA was measured as a reduc-
tion in, and expressed as percentage of, p24 production
(measured as pg/ml) relative to p24 production from cells
transfected with the corresponding empty expression con-
trol plasmid. The 96 shRNAs were measured in 3 sets with
2 or more replicate experiments in each set (accessory
gene shRNAs in one set, Gag plus Env shRNAs together,
and Pol shRNAs separately), with 95% confidence inter-
vals shown. The values from each experiment were
adjusted relative to minor changes in an internal control
shRNA common to all experiments to allow comparison
of the different shRNAs across experiments (#61, Tat143-
21).
Statistical analysis
All error bars on activity graphs were 95% confidence
intervals (CI) (Microsoft Excel X for Mac, 2001). P values
were determined as individually described using Graph-
pad Prism 4.0a for Mac OS X, 2003.
Figure preparation
Figures were prepared by http://www.FigureMe
Happy.com
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